Periprocedural Myocardial Infarction and Mortality: Causality Versus Association

Journal of the American College of Cardiology

Volumn 42, Issue 8, 2003, Pages 1412-1414

  Nallamothu, Brahmajee K ^a   Bates, Eric R ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOENZYME; TROPONIN;

ANGIOPLASTY; ATHERECTOMY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DISEASE MARKER; EDITORIAL; HEART ARRHYTHMIA; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0142075773     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)01037-4     Document Type: Editorial

References (26)

1. Ioannidis JPA, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 2003;42:1406-11.
2. Abdelmeguid AE, Topol EJ. The myth of the myocardial 'infarctlet' during percutaneous coronary revascularization procedures. Circulation 1996;94:3369-75.
3. Holmes DR Jr., Berger PB. Troponisms, necrosettes, enzyme leaks, creatinine phosphokinase bumps, and infarctlets. What's behind this new lexicon and what does it add? Circulation 2001;104:627-9.
4. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q-wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991;17:621-6.
5. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996;94:1528-36.
6. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997;277:461-6.
7. Kini A, Marmur JD, Kini S, et al. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. J Am Coll Cardiol 1999; 34:663-71.
8. Ellis SG, Chew D, Chan A, Whitlow PL, Schneider JP, Topol EJ. Death following creatine kinase-MB elevation after coronary intervention: identification of an early risk period: importance of creatine kinase-MB level, completeness of revascularization, ventricular function, and probable benefit of statin therapy. Circulation 2002;106: 1205-10.
9. Nallamothu BK, Chetcuti S, Mukherjee D, et al. Prognostic implication of troponin-I after percutaneous coronary intervention. Am J Cardiol 2003;91:1272-4.
10. Harrington RA, Lincoff AM, Califf RM, et al. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J Am Coll Cardiol 1995;25: 1693-9.
11. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352:87-92.
12. Califf RM, Abdelmeguid AE, Kuntz RE, et al. Myonecrosis after revascularization procedures. J Am Coll Cardiol 1998;31:241-51.
13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
14. Smith SC Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37: 2215-39.
15. Levine GN, Kern MJ, Berger PB, et al. Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003;139:123-36.
16. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001;103: 2780-3.
17. Kanaparti PK, Brown DL. Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. Am J Cardiol 2000;86:619-22.
18. Mehran R, Dangas G, Mintz GS, et al. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: intravascular ultrasound study of 2256 patients. Circulation 2000;101:604-10.
19. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
20. Sharma SK, Kini A, Marmur JD, Fuster V. Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. Circulation 2000;102:166-72.
21. Herrmann J, Lerman A, Baumgart D, et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 2002;106:2180-3.
22. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999;99:2085-9.
23. Desmet W, Dens J, Coussement P, Van de Werf F. Does adenosine prevent myocardial micronecrosis following percutaneous coronary intervention? The ADELINE pilot trial. Heart 2002;88:293-5.
24. Ellis SG, Brener SJ, Lincoff AM, et al. Beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme rise. Circulation 2001;104:2685-8.
25. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-90.
26. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6.